Evidence map›Paper›PMID 39302055›Full record

ArticleJournal of global health2024

Lifetime cost-effectiveness of myopia control intervention for the children population.

Ching So, Jinxiao Lian, Sarah Morag McGhee, Rita Wing Man Sum, Andrew Kwok Cheung Lam, Maurice Keng Hung Yap

Abstract read
In one paragraph

Article in Journal of global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. The Long-Term Patient Journey with DIMS Spectacle Lenses: A Mixed-Methods Study of Satisfaction, Adherence and Socioeconomic Barriers.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026
    Article
  4. The prevalence and costs of optical correction for childhood myopia in Scotland.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ching SoSchool of Optometry, The Hong Kong Polytechnic University, Hong Kong SAR, China.
Jinxiao LianSchool of Optometry, The Hong Kong Polytechnic University, Hong Kong SAR, China.
Sarah Morag McGheeSchool of Public Health, The University of Hong Kong, Hong Kong SAR, China.
Rita Wing Man SumSchool of Optometry, The Hong Kong Polytechnic University, Hong Kong SAR, China.
Andrew Kwok Cheung LamSchool of Optometry, The Hong Kong Polytechnic University, Hong Kong SAR, China.
Maurice Keng Hung YapSchool of Optometry, The Hong Kong Polytechnic University, Hong Kong SAR, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Myopia is a common eye condition and projected to affect half of the global population by 2050. Controlling its progression during childhood may prevent associated ocular diseases in later life. Certain interventions retard myopia progression but their long-term costs and consequences are not well understood. We evaluated the cost-effectiveness of myopia control via an optical approach using the Defocus Incorporated Multiple Segments (DIMS) lens over a lifetime. Methods: We constructed an individual-based, state-transition model to simulate 1) the development and progression of myopia in childhood with and without control and 2) the impact of myopia on the development of four sight-threatening complications in adulthood. We compared strategies of myopia control with 100% uptake vs. no myopia control from the societal perspective to determine whether myopia control is value for money. Results: With myopia control, the cumulative prevalence of high myopia was relatively reduced by 44.7% (5.9 vs. 10.7%) and severe visual impairment by 19.2% (2.2 vs. 2.7%) compared to no myopia control. The lifetime cost per quality-adjusted life year gained was 26 407 US dollars (USD) and is considered cost-effective compared to the threshold recommended by the World Health Organization (WHO) of one times annual per capita gross domestic product (48 359 USD). Probabilistic sensitivity analysis showed that myopia control had an 87% likelihood of being cost-effective at the WHO threshold. Conclusions: Myopia control is cost-effective when provided to all eligible children. Further investigation is required to determine if it is cost-effective for the government to subsidise myopia control in order to maximise access.

Indexed as

Cost-Benefit AnalysisMyopiaAdolescentAdultChildChild, PreschoolFemaleHumansMaleQuality-Adjusted Life Years

Identifiers

PMID39302055
PMCPMC11414424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.